Skip to main content

Afluria Quadrivalent FDA Approval History

Last updated by Judith Stewart, BPharm on Oct 28, 2020.

FDA Approved: Yes (First approved August 26, 2016)
Brand name: Afluria Quadrivalent
Generic name: influenza virus vaccine, inactivated
Dosage form: Injection
Company: Seqirus
Treatment for: Influenza Prophylaxis

Afluria Quadrivalent is an inactivated influenza virus vaccine indicated for active immunization against influenza disease in persons 6 months of age and older.

Development timeline for Afluria Quadrivalent

DateArticle
Oct 23, 2018Approval Seqirus Receives FDA Approval of Afluria and Afluria Quadrivalent (Influenza Vaccine) for People Six Months of Age and Older in the U.S.
Sep 14, 2017Approval Seqirus Receives FDA Approval of Afluria Quadrivalent (Influenza Vaccine) for People Five Years of Age and Older in the U.S.
Aug 29, 2016Approval Seqirus Receives FDA Approval for Afluria Quadrivalent (Influenza Vaccine) for People 18 Years of Age and Older

See also

Afluria Quadrivalent (influenza virus vaccine, inactivated) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer